Incidence of acute phase reactions (APRs) in patients with advanced cancer or multiple myeloma (MM) And bone metastases/lesions following treatment with denosumab or zoledronic acid (ZA)     (#815)
    
  
  
                                                                              
  Nina  Singh RN
      1
  
, 
  Cynthia Campbell-Baird RN, OCN
      2
  
, 
  Hans Polderdijk RN
      3
  
, 
  Stacey Harrelson RN
      4
  
, 
  Judith Buechel RN
      5
  
, 
  Tap Maniar MD
      6
  
    
              - Sydney Haematology and Oncology Clinics Clinical Trials Unit, Sydney Adventist Hospital, Wahroonga, NSW, Australia
 
              - Penn State Milton S. Hershey Medical Center, Hershey, PA, USA
 
              - HagaZiekenhuis-Leyenburg, Den Haag, Netherlands
 
              - Carolina Urologic Research Center, Myrtle Beach, South Carolina, USA
 
              - Haematology and Oncology, Innsbruck University Hospital, Inssbruck, Austria
 
              - Amgen Inc., Thousand Oaks, CA, USA